n1.Do the safety and efficacy data
presented support accelerated approval of
maraviroc for treatment-experienced HIV-1
infected patients with CCR5-tropic virus?
not, please discuss what additional data are needed to provide sufficient evidence of efficacy and
so, please comment on additional data (e.g., patient subgroups, longer term follow-up, etc.) that Pfizer
post-marketing to further characterize the safety and efficacy profile of maraviroc